BYL719 (CAS 1217486-61-7)
See product citations (2)
QUICK LINKS
BYL719 is a cutting-edge inhibitor of phosphoinositide-3-kinase (PI3K), an enzyme playing a pivotal role in the regulation of cell growth, proliferation, and survival. PI3K is often found to be overly active in cancer cells, contributing to their unchecked proliferation and survival. BYL719 targets and inhibits PI3K, disrupting its activity and thereby impeding the growth of cancer cells. This action is particularly significant in the context of oncological research, where understanding the mechanisms by which cancer cells evade normal growth controls is crucial. By inhibiting PI3K, BYL719 offers insights into the potential modulation of cellular pathways that are critical for cancer cell survival. This approach underscores the importance of targeting specific molecular pathways in research aimed at understanding the complex biology of cancer.
BYL719 (CAS 1217486-61-7) References
- BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. | Gobin, B., et al. 2015. Int J Cancer. 136: 784-96. PMID: 24961790
- BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. | Ku, BM., et al. 2015. Invest New Drugs. 33: 12-21. PMID: 25342139
- Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. | Juric, D., et al. 2018. J Clin Oncol. 36: 1291-1299. PMID: 29401002
- PI3K Inhibitors in Breast Cancer Therapy. | Ellis, H. and Ma, CX. 2019. Curr Oncol Rep. 21: 110. PMID: 31828441
- PIK3CA vascular overgrowth syndromes: an update. | Hughes, M., et al. 2020. Curr Opin Pediatr. 32: 539-546. PMID: 32692051
- PI3K inhibitors: review and new strategies. | Zhang, M., et al. 2020. Chem Sci. 11: 5855-5865. PMID: 32953006
- PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy. | Chuang, FC., et al. 2021. PLoS One. 16: e0245715. PMID: 33471836
- Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet. | Hedges, CP., et al. 2021. Biomolecules. 11: PMID: 33503847
- ASCO 2020: highlights in breast cancer. | Bartsch, R. 2021. Memo. 14: 58-61. PMID: 33520003
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. | Rugo, HS., et al. 2021. Lancet Oncol. 22: 489-498. PMID: 33794206
- PI3K inhibitors are finally coming of age. | Vanhaesebroeck, B., et al. 2021. Nat Rev Drug Discov. 20: 741-769. PMID: 34127844
- A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. | Canaud, G., et al. 2021. Orphanet J Rare Dis. 16: 306. PMID: 34238334
- Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. | Burstein, HJ., et al. 2021. J Clin Oncol. 39: 3959-3977. PMID: 34324367
- BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer. | Bogani, G., et al. 2023. Tumori. 109: 244-248. PMID: 35311394
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BYL719, 5 mg | sc-391001 | 5 mg | $391.00 | |||
BYL719, 10 mg | sc-391001A | 10 mg | $597.00 | |||
BYL719, 50 mg | sc-391001B | 50 mg | $755.00 | |||
BYL719, 100 mg | sc-391001C | 100 mg | $1192.00 | |||
BYL719, 500 mg | sc-391001D | 500 mg | $5000.00 | |||
BYL719, 1 g | sc-391001E | 1 g | $9370.00 |